13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q3 2018. See the latest, Q3 2026 →

Reported value

$13.06B

+14% on the quarter before

Positions

38

6 new, 1 sold out

Top 10

72.0%

of the value

Est. gain

−$118.7M

on stocks held all quarter

Est. return

−1.2%

on those stocks since Q2 2018

Filed

Nov 15, 2018 (amended)

On SEC EDGAR ↗

Positions as of Sep 30, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2018. Striped tiles are options.

Twenty First Centy Fox Inc18%
Cheniere Energy Inc7.6%
Allergan Plc7.2%
Viasat Inc6.7%
Pg&E Corp6.7%
Qorvo6.5%
Twenty First Centy Fox Inc6.1%
Pioneer Nat Res Co5.3%
Synchrony Finl3.9%
14 others3.8%
Antero Res Corp3.6%
Tesla2.4%
Theravance Biopharma Inc2.3%
Liberty Global Plc2.3%
Colony Cap Inc New2.3%
Mckesson Corp2.2%
Atara Biotherapeutics Inc2.0%
Cardinal Health Inc2.0%
Amerisourcebergen Corp1.9%
Tribune Media Co1.8%
Altaba Inc1.5%
Liberty Global Plc1.1%
Veritiv Corp1.0%
0.7%
0.7%

Largest buys

Since Q2 2018, sized at quarter-end prices.

  1. Pg&E Corp~$666.2MAdded, 1.7% → 6.7% of the portfolio+14,479,790 shares
  2. Twenty First Centy Fox Inc~$583.1MAdded, 17.1% → 18.5% of the portfolio+12,585,338 shares
  3. Liberty Global Plc~$303.3MNew, 0.0% → 2.3% of the portfolio+10,768,870 shares
  4. Altaba Inc~$191.5MNew, 0.0% → 1.5% of the portfolio+2,810,775 shares
  5. Twenty First Centy Fox Inc~$170.2MAdded, 5.9% → 6.1% of the portfolio+3,714,662 shares
  6. Liberty Global Plc~$143.4MNew, 0.0% → 1.1% of the portfolio+4,957,205 shares
  7. Tribune Media Co~$115.3MAdded, 1.0% → 1.8% of the portfolio+3,000,000 shares
  8. Ypf Sociedad Anonima~$92.7MNew, 0.0% → 0.7% of the portfolio+6,000,000 shares
  9. Amerisourcebergen Corp~$80.9MAdded, 1.4% → 1.9% of the portfolio+877,491 shares
  10. Mckesson Corp~$72.7MAdded, 1.9% → 2.2% of the portfolio+548,000 shares

Largest sells

Since Q2 2018, sized at quarter-end prices.

  1. Synchrony Finl~$402.9MCut, 8.5% → 3.9% of the portfolio−12,962,101 shares
  2. AT&T~$304.4MSold out, 2.7% → 0.0% of the portfolio−9,480,700 shares
  3. Amc Entmt Hldgs Inc~$46.5MCut, 0.7% → 0.4% of the portfolio−2,268,700 shares
  4. Cardinal Health Inc~$19.5MCut, 2.2% → 2.0% of the portfolio−361,515 shares
  5. Veritiv Corp~$9.5MCut, 1.3% → 1.0% of the portfolio−259,946 shares

Holdings

As of Sep 30, 2018; changes in shares since Jun 30, 2018.

Positions, sorted by share of the portfolio
HoldingValue
Twenty First Centy Fox IncCL A · shares +32% · price −6.8%18.5%$2.41B−$132.4M
Cheniere Energy IncCOM NEW · shares 0% · price +6.6%7.6%$986.5M+$61.0M
Allergan PlcSHS · shares 0% · price +14.3%7.2%$942.9M+$117.6M
Viasat IncCOM · shares 0% · price −2.7%6.7%$878.2M−$24.3M
Pg&E CorpCOM · shares +322% · price +8.1%6.7%$873.3M+$15.5M
QorvoCOM · shares 0% · price −4.1%6.5%$845.8M−$36.1M
Twenty First Centy Fox IncCL B · shares +27% · price −7.0%6.1%$793.6M−$46.9M
Pioneer Nat Res CoCOM · shares 0% · price −8.0%5.3%$696.8M−$60.2M
Synchrony FinlCOM · shares −44% · price −6.9%3.9%$507.6M−$37.6M
Antero Res CorpCOM · shares 0% · price −17.0%3.6%$470.9M−$96.8M
TeslaNOTE 2.375% 3/1 · shares +20% · price −16.0%2.4%$308.6M—
Theravance Biopharma IncCOM · shares 0% · price +44.0%2.3%$304.1M+$93.0M
Liberty Global PlcSHS CL C · shares New2.3%$303.3M—
Colony Cap Inc NewCL A COM · shares 0% · price −2.4%2.3%$302.6M−$7.5M
Mckesson CorpCOM · shares +34% · price −0.6%2.2%$288.6M−$1.2M
Atara Biotherapeutics IncCOM · shares 0% · price +12.5%2.0%$258.6M+$28.8M
Cardinal Health IncCOM · shares −7.1% · price +10.6%2.0%$255.9M+$24.5M
Amerisourcebergen CorpCOM · shares +47% · price +8.2%1.9%$253.7M+$13.0M
Tribune Media CoCL A · shares +100% · price +0.4%1.8%$230.4M+$478,947
Altaba IncCOM · shares New1.5%$191.5M—
Liberty Global PlcSHS CL A · shares New1.1%$143.4M—
Veritiv CorpCOM · shares −6.8% · price −8.7%0.99%$129.7M−$12.3M
Ypf Sociedad AnonimaSPON ADR CL D · shares New0.71%$92.7M—
Keryx Biopharmaceuticals IncCOM · shares 0% · price −9.6%0.67%$87.7M−$9.3M
Sinclair Broadcast Group IncCL A · shares +17% · price −11.8%0.65%$85.0M−$9.8M
Total 38 positions100%$13.06B−$118.7M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2018 to Q3 2018: 30 stocks held throughout, down $118.7M (−1.2%).

  1. Allergan Plc+$117.6M+14%
  2. Theravance Biopharma Inc+$93.0M+44%
  3. Cheniere Energy Inc+$61.0M+7%
  4. Atara Biotherapeutics Inc+$28.8M+13%
  5. Cardinal Health Inc+$24.5M+11%
  6. Synchrony Finl−$37.6M−7%
  7. Twenty First Centy Fox Inc−$46.9M−7%
  8. Pioneer Nat Res Co−$60.2M−8%
  9. Antero Res Corp−$96.8M−17%
  10. Twenty First Centy Fox Inc−$132.4M−7%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free